Biomerica Inc
BMRA Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 23, 2026
$1.68
KIRA · Stoqly’s AI analyst, in plain words
- Biomerica Inc had $4.5M of revenue in fiscal 2026, down 16.2% on the year before. Over five years, revenue changed −9.2% a year on average.
- Its operating margin was −119.5%, down 22.7 pts: of every 100 in sales, about −119 is left after running the business.
- Biomerica Inc lost $3.8M in fiscal 2026.
Market cap
$5.5M
P/E
—
Revenue
$4.5M
Net income
−$3.8M
Free cash flow
—
Operating margin
−119.5%
Biomerica Inc in 30 seconds · fiscal 2026
Are sales growing?
−16.2%
No. Sales fell 16.2% last year.
Does it make a profit?
−84.8%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biomerica Inc does
No business description yet.
- Fiscal year ends
- May 31, 2026
- Latest annual report
- 10-K · Aug 31, 2026
- Legal name
- BIOMERICA INC
- CIK
- 0000073290
Biomerica Inc · BMRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Revenue growth | 162.1% | −71.7% | 1.4% | −1.9% | −16.2% |
| Gross margin | 15.8% | 8.4% | 11.3% | 9.4% | 8.1% |
| Operating margin | −24.0% | −135.3% | −117.6% | −96.7% | −119.5% |
| Net income | −$4.5M | −$7.1M | −$6.0M | −$5.0M | −$3.8M |
| Net margin | −24.0% | −133.7% | −110.4% | −93.6% | −84.8% |
| Diluted EPS | −$0.36 | −$0.50 | −$2.84 | −$2.16 | −$1.30 |
| Cash | |||||
| Cash from operations | −$0.5M | −$5.5M | −$5.4M | −$3.8M | −$3.4M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | — | — |
| Free cash flow | −$0.5M | −$5.5M | −$5.4M | — | — |
| FCF margin | −2.8% | −103.7% | −99.9% | — | — |
| Share count change | 6.2% | 11.7% | −85.1% | 9.2% | 26.9% |
| Debt and strength | |||||
| Cash and short-term investments | $5.9M | $9.7M | $4.2M | $2.4M | $1.3M |
| Shareholders' equity | $8.3M | $11.7M | $6.6M | $4.1M | $2.6M |
| Current ratio | 4.7x | 6.6x | 3.5x | 2.8x | 1.6x |
| Returns and quality | |||||
| Return on equity | −51.6% | −71.2% | −65.3% | −93.0% | −112.1% |
| Return on tangible equity | −55.6% | −61.8% | −93.7% | −128.3% | −155.9% |
| Piotroski F-score | 4 | 2 | 4 | 2 | 2 |
| Altman Z'' | −5.6 | −3.4 | −15.1 | −29.2 | −30.6 |
Insiders bought, 12 months
$0.2M
5 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biomerica Inc · BMRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.68 a share, the company is worth $5.5M.
Source: SEC EDGAR XBRL filings (CIK 0000073290). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.